This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database.
All Wales Medicines Strategy Group (AWMSG). Ledipasvir/sofosbuvir (Harvoni®) Penarth: All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG). AWMSG Secretariat Assessment Report Advice No. 1887. 2015
Ledipasvir/sofosbuvir (Harvoni®) is recommended as an option for restricted use within NHS Wales for the treatment of chronic hepatitis C in adults with hepatitis C virus genotype 1 and 4 without cirrhosis or with compensated cirrhosis for up to 12 weeks. Ledipasvir/sofosbuvir (Harvoni®) is not recommended for use within NHS Wales outside of this subpopulation/these circumstances. Key factor(s) influencing the recommendation: The cost effectiveness data presented in the submission were insufficient for AWMSG to recommend use beyond 12 weeks. No economic data were provided for genotype 1 or 4 patients with decompensated cirrhosis or who are pre-/post liver transplant. Similarly, no economic data were provided for genotype 3 patients with cirrhosis and/or prior treatment failure.
Subject indexing assigned by CRD
Anti-Retroviral Agents; Antiviral Agents; Benzimidazoles; Drug Therapy, Combinations; Fluorenes; Uridine Monophosphate
Country of organisation
An English language summary is available.
Address for correspondence
All Wales Therapeutics and Toxicology Centre, Academic Centre, University Hospital Llandough, Penlan Road, Penarth, Vale of Glamorgan CF64 2XX
Date abstract record published